The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

Assistant U.S. Attorney Roger Stefin claimed some of Melgen's patients developed serious eye infections from unnecessary Lucentis injections administered on the basis of bogus macular degeneration ...

In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...

The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...